Cordesin Dosage

• Dosage of Magnesium Aspartate (Cordesin) in details
• Magnesium Aspartate (Cordesin) interactions
• Dosage of Potassium Aspartate (Cordesin) in details
• Potassium Aspartate (Cordesin) interactions
• Cordesin reviews

Consists of Magnesium Aspartate, Potassium Aspartate

Dosage of Magnesium Aspartate (Cordesin) in details

Dosage of Magnesium Aspartate (Cordesin) sulfate must be carefully adjusted according to individual requirements and response, and administration of the drug should be discontinued as soon as the desired effect is obtained.

Both intravenous and intramuscular administration are appropriate.

Intramuscular administration of the undiluted 50% solution results in therapeutic plasma levels in 60 minutes, whereas intravenous doses will provide a therapeutic level almost immediately. The rate of intravenous injection should generally not exceed 150 mg/minute (1.5 mL of a 10% concentration or its equivalent), except in severe eclampsia with seizures. Continuous maternal administration of Magnesium Aspartate (Cordesin) sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities.

Solutions for intravenous infusion must be diluted to a concentration of 20% or less prior to administration. The diluents commonly used are 5% Dextrose Injection, USP and 0.9% Sodium Chloride Injection, USP. Deep intramuscular injection of the undiluted (50%) solution is appropriate for adults, but the solution should be diluted to a 20% or less concentration prior to such injection in children.

In Magnesium Aspartate (Cordesin) Deficiency

In the treatment of mild Magnesium Aspartate (Cordesin) deficiency, the usual adult dose is 1 gram, equivalent to 8.12 mEq of Magnesium Aspartate (Cordesin) (2 mL of the 50% solution) injected intramuscularly every six hours for four doses (equivalent to a total of 32.5 mEq of Magnesium Aspartate (Cordesin) per 24 hours). For severe hypomagnesemia, as much as 250 mg (approximately 2 mEq) per kg of body weight (0.5 mL of the 50% solution) may be given intramuscularly within a period of four hours if necessary. Alternatively, 5 grams, (approximately 40 mEq) can be added to one liter of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP for slow intravenous infusion over a three-hour period. In the treatment of deficiency states, caution must be observed to prevent exceeding the renal excretory capacity.

In Hyperalimentation

In total parenteral nutrition, maintenance requirements for Magnesium Aspartate (Cordesin) are not precisely known. The maintenance dose used in adults ranges from 8 to 24 mEq (1 gram to 3 grams) daily; for infants, the range is 2 to 10 mEq (0.25 gram to 1.25 grams) daily.

In Pre-eclampsia or Eclampsia

In severe pre-eclampsia or eclampsia, the total initial dose is 10 grams to 14 grams of Magnesium Aspartate (Cordesin) sulfate.

Intravenously, a dose of 4 grams to 5 grams in 250 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP may be infused. Simultaneously, intramuscular doses of up to 10 grams (5 grams or 10 mL of the undiluted 50% solution in each buttock) are given. Alternatively, the initial intravenous dose of 4 grams may be given by diluting the 50% solution to a 10 or 20% concentration; the diluted fluid (40 mL of a 10% solution or 20 mL of a 20% solution) may then be injected intravenously over a period of three to four minutes. Subsequently, 4 grams to 5 grams (8 to 10 mL of the 50% solution) are injected intramuscularly into alternate buttocks every four hours as needed, depending on the continuing presence of the patellar reflex and adequate respiratory function. Alternatively, after the initial intravenous dose, some clinicians administer 1 gram to 2 grams/hour by constant intravenous infusion. Therapy should continue until paroxysms cease. A serum Magnesium Aspartate (Cordesin) level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hr) dose of 30 grams to 40 grams should not be exceeded. In the presence of severe renal insufficiency, the maximum dosage of Magnesium Aspartate (Cordesin) sulfate is 20 grams/48 hours and frequent serum Magnesium Aspartate (Cordesin) concentrations must be obtained. Continuous use of Magnesium Aspartate (Cordesin) sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities.

Other Uses

In counteracting the muscle-stimulating effects of barium poisoning, the usual dose of Magnesium Aspartate (Cordesin) sulfate is 1 gram to 2 grams given intravenously.

For controlling seizures associated with epilepsy, glomerulonephritis or hypothyroidism, the usual adult dose is 1 gram administered intramuscularly or intravenously.

In paroxysmal atrial tachycardia, Magnesium Aspartate (Cordesin) should be used only if simpler measures have failed and there is no evidence of myocardial damage. The usual dose is 3 grams to 4 grams (30 to 40 mL of a 10% solution) administered intravenously over 30 seconds with extreme caution.

For reduction of cerebral edema, 2.5 grams (25 mL of a 10% solution) is given intravenously.

Incompatibilities

Magnesium Aspartate (Cordesin) sulfate in solution may result in a precipitate formation when mixed with solutions containing:

Alcohol (in high Heavy Metals

concentrations) Hydrocortisone sodium

Alkali carbonates and succinate

bicarbonates Phosphates

Alkali hydroxides Polymixin B sulfate

Arsenates Procaine hydrochloride

Barium Salicylates

Calcium Strontium

Clindamycin phosphate Tartrates

The potential incompatibility will often be influenced by the changes in the concentration of reactants and the pH of the solutions.

It has been reported that Magnesium Aspartate (Cordesin) may reduce the antibiotic activity of streptomycin, tetracycline and tobramycin when given together.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

What other drugs will affect Magnesium Aspartate (Cordesin)?

Certain antibiotics should not be taken at the same time as Magnesium Aspartate (Cordesin) gluconate because they may not be absorbed as well by your body. If you are taking an antibiotic, avoid taking it within 2 hours before or after you take Magnesium Aspartate (Cordesin) gluconate.

Before taking Magnesium Aspartate (Cordesin) gluconate, tell your doctor if you are using any of the following drugs:

• naladixic acid (NegGram);

• penicillamine (Cuprimine, Depen);

• an antibiotic such as tetracycline (Brodspec, Sumycin, Tetracap, and others), demeclocycline (Declomycin), doxycycline (Vibramycin, Monodox, Doryx, Doxy, and others), or minocycline (Minocin, Dynacin, and others);

• a fluoroquinolone antibiotic such as ciprofloxacin (Cipro), gatifloxacin (Tequin), levofloxacin (Levaquin), lomefloxacin (Maxaquin), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), sparfloxacin (Zagam), or trovafloxacin (Trovan); or

• a medication for osteoporosis or Paget's disease, such as alendronate (Fosamax), etidronate (Didronel), ibandronate (Boniva), risedronate (Actonel), or tiludronate (Skelid).

If you are using any of these drugs, you may not be able to use Magnesium Aspartate (Cordesin) gluconate, or you may need dosage adjustments or special tests during treatment.

There may be other drugs not listed that can affect Magnesium Aspartate (Cordesin) gluconate. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Magnesium Aspartate (Cordesin) interactions

If you are taking this product under your doctor's direction, your doctor or pharmacist may already be aware of possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first.

Before using this product, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: cellulose sodium phosphate, digoxin, sodium polystyrene sulfonate.

Magnesium Aspartate (Cordesin) can bind with certain medications, preventing their full absorption. If you are taking a tetracycline-type medication (such as demeclocycline, doxycycline, minocycline, tetracycline), separate the time of the dose from the time of the Magnesium Aspartate (Cordesin) supplement dose by at least 2 to 3 hours. If you are taking a bisphosphonate (for example, alendronate), a thyroid medication (for example, levothyroxine), or a quinolone-type antibiotic (e.g., ciprofloxacin, levofloxacin), ask your doctor or pharmacist about how long you should wait between doses and for help finding a dosing schedule that will work with all your medications.

Check the labels on all your prescription and nonprescription/herbal products (e.g., antacids, laxatives, vitamins) because they may contain Magnesium Aspartate (Cordesin). Ask your pharmacist about using those products safely.

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

Dosage of Potassium Aspartate (Cordesin) in details

1 pack to be dissolved in water to make about 2 L soln.

Orally administer 2-4 L of the soln at a rate of 1 L/hr. Discontinue dosing at the time excretion liqd becomes clear.

Potassium Aspartate (Cordesin) interactions

Disturbs absorption of orally administered drugs.

References

1. FDA/SPL Indexing Data. "RWP5GA015D: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
2. MeSH. "MeSH Tree: MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.". http://www.nlm.nih.gov/mesh/meshhome... (accessed September 17, 2018).
3. European Chemicals Agency - ECHA. "Potassium: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology